
About Embecta
Embecta is a publicly listed company based in Parsippany (United States) founded in 2022. Insulin delivery solutions including pen needles and syringes are manufactured. The company has 2,100 employees. Embecta has completed 1 acquisition, including Owen Mumford. Its chief executive, as recorded, is Devdatt Kurdikar. Its website embecta.com draws about 60 thousand monthly visits. Its Indian entity Embecta India Private Limited reported revenue of ₹24.06 Cr. Embecta offers products and services including Pen Needles and Insulin Syringes. Its focus areas include Life Sciences, Diabetes, Medical Devices and Therapeutic Devices.
Company details
Embecta was founded in 2022 and is headquartered in Parsippany, United States. Operations are centered in the healthcare sector, with a focus on diabetes management. Insulin delivery products such as pen needles and syringes are developed and supplied to support daily care needs. Efforts are directed toward enhancing injection experiences through innovation. Educational resources and guidance on proper injection techniques are also made available to users.
- Indian entity revenue₹24.06 Cr
FY 2025 · +6% YoY
- Indian entity net profit₹49.8 Lakh
FY 2025 · 2% margin
- Indian entity EBITDA₹3.11 Cr
FY 2025 · 13% margin
- Employee Count2,100
- Investments & Acquisitions
Associated legal entities of Embecta
Embecta operates through Embecta India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Embecta India Private Limited CIN U51909HR2021FTC115336 | Active | 03 Nov 2021 | Gurgaon, Haryana | ₹24.1 Cr | 39 | 3 | View details |
Products & Services of Embecta
Embecta offers a comprehensive portfolio of products and services, including Pen Needles and Insulin Syringes.
Pen needles are manufactured for use in insulin delivery to aid diabetes management.
Insulin syringes are supplied for administering insulin as part of diabetes care practices.
Apps and channels of Embecta
its YouTube channel embecta has 676 subscribers and 30 videos.
Videos from Embecta
The most watched videos on Embecta's YouTube channel, embecta (676 subscribers). Click a video to play it here.
More on embecta.
Board of directors of Embecta India Private Limited (Embecta)
Embecta India Private Limited is the primary company behind Embecta. The board of Embecta India Private Limited currently have 3 directors; the longest-serving is Sushil Shadija, appointed in 2022. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sushil Shadija DIN 09523985 | Whole-time director | 15 Mar 2022 | 4 yrs 8 mo | Embecta India Private Limited |
| Jeffrey Zimmerman Mann DIN 09526647 | Director | 15 Mar 2022 | 4 yrs 8 mo | Embecta India Private Limited |
| Michael John Piotrowski DIN 10848120 | Director | 06 Dec 2024 | 1 yr 11 mo | Embecta India Private Limited |
People of Embecta
79 people are tracked at Embecta (49 in leadership, 30 in team); the tracked headcount is 2,100.
| Name | Role | Group |
|---|---|---|
Devdatt Kurdikar | CEO | Leadership |
Jean Casner | Sr. Vice President & CHRO | Leadership |
Arpan Gandhi | Senior Director - National Sales And GPO | Leadership |
Avital Merl-Margulies | Senior Director, Regulatory Compliance | Leadership |
Rachael Roberts | Vice President Of Sales | Leadership |
Christine Seethaler | Head Of Legal Operations | Leadership |
Ketan D. Patel | Vice President Of Tax | Leadership |
Geoff Sisler | Vp, Total Rewards & HR Operations | Leadership |
Donald Broedlin | Vice President, Strategic Accounts | Leadership |
Antonio Mulé | Vice President, Global Commercial Finance | Leadership |
Jake Elguicze | Svp, Chief Financial Officer | Leadership |
Roberto Bettin | Amministratore Delegato - General Manager, Southern Europe | Leadership |
Nirav Panchal | Associate Director | Leadership |
Claudia Karpat | Legal Director EMEA Region & Corporate International | Leadership |
Katie Ellis | Key Account Director- Retail & Distribution | Leadership |
Ray Jacobus | Senior Director Strategic Pricing & Contracting - North America | Leadership |
Ashley Caldwell | Senior Director, Retail And Distribution | Leadership |
Shoua X. | Sr. Director, North America Commercial And Global Head Of Ethics, Compliance And Privacy | Leadership |
Elyse Robertson | Sr. Director HR | Leadership |
Adam Hansinger | National Account Director | Leadership |
59 more people are available in the full profile.
Complete people profiles for Embecta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Embecta
Embecta is a publicly listed company on the NASDAQ with ticker symbol EMBC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Mar 2022
- Listed onNASDAQ: EMBC
- Listed entityEmbecta Corp.
- Exchange sectorHealth technology
- ISINUS29082K1051
- Share price$6.20 (+3.51% on the day) · 2026-10-13
- Market capitalisation$351.3M
- Price to earnings4.2
- EPS (diluted, trailing year)$1.48
- Dividend yield5.16%
- Volume (last session)732,864
Financials of Embecta
Figures of Embecta India Private Limited, the primary company behind Embecta, for FY 2025. Revenue was ₹24.06 Cr (+6% year on year). Net profit was ₹49.8 Lakh (2% margin). EBITDA was ₹3.11 Cr (13% margin). Revenue has grown at a compounded annual rate of +204% over three years.
- ₹24.06 CrRevenue · FY 2025 · +6% YoY
- ₹49.8 LakhNet profit · 2% margin
- ₹3.11 CrEBITDA · 13% margin
- ₹6 LakhPaid-up capital
- 39Employees (provident fund records)
- +204%Revenue CAGR, 3 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.08B | $95.4M | $380.4M |
| 2024 | $1.12B | $78.3M | $216.7M |
| 2023 | $1.12B | $70.4M | $262.3M |
| 2022 | $1.13B | $223.6M | $409.8M |
| 2021 | $1.17B | $415.0M | $530.0M |
Balance sheet, profit and loss, cash flow and ratios of Embecta India Private Limited are on its company page.
Detailed financial statements for Embecta
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Embecta
Embecta has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Owen Mumford.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Disposables for drug delivery and capillary blood sampling are manufactured. | owenmumford.com | Oxford, United Kingdom | 1952 | Mar 2026 | $200.08M |
Complete acquisition details for Embecta
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Embecta
3 dated milestones of Embecta across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Embecta is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Owen Mumford.
Web traffic of Embecta
The website of Embecta (embecta.com) receives about 60.1K visits a month.
- Monthly visits60.1K
▼ 13.9% vs previous month
Websites whose visitors overlap most with Embecta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
medicinalsupplies.com | medicinalsupplies.com | 100% | #2,604,369 | – |
Top companies in Diabetes
3 companies that operate in the same segment as Embecta (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Embecta
Complete news archive for Embecta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Embecta
Embecta was founded in 2022.
Embecta is headquartered in Parsippany, United States. It is registered at Parsippany, New Jersey, United States.
Devdatt Kurdikar is the CEO of Embecta, as recorded in our data.
Embecta has 2,100 employees.
The primary company behind Embecta, Embecta India Private Limited, reported revenue of ₹24.06 Cr for FY 2025, up 6% year on year.
Embecta was founded in 2022 and is headquartered in Parsippany, United States. Operations are centered in the healthcare sector, with a focus on diabetes management. Insulin delivery products such as pen needles and syringes are developed and supplied to support daily care needs. Efforts are directed toward enhancing injection experiences through innovation. Educational resources and guidance on proper injection techniques are also made available to users.
Embecta offers Pen Needles and Insulin Syringes.
Yes, Embecta is publicly traded on NASDAQ under the ticker symbol EMBC.
Embecta has made 1 acquisition, including Owen Mumford.
Embecta operates through Embecta India Private Limited.
The legal entities of Embecta currently have 3 directors, including Sushil Shadija, Jeffrey Zimmerman Mann, Michael John Piotrowski.
